我要投票 以岭药业在中草药行业中的票数:334
· 外 推 电 报 ·
2025-06-19 09:31:46 星期四

【以岭药业是哪个国家的品牌?】

以岭药业是什么牌子?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力以岭药业品牌出海!将品牌入驻外推网,定制以岭药业品牌推广信息,可以显著提高以岭药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

英文翻译:Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://www.waitui.com/brand/887854f10.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

公募基金半年收益榜“剧透”,创新药配置价值凸显

Wind资讯数据显示,截至6月18日,医药类基金以平均超19%的净值增长率脱颖而出,在年内基金收益排名前100名中占据近“半壁江山”,引发市场对医药板块尤其是创新药领域配置价值的广泛关注。创新药作为医药板块中具备较好成长性和产业逻辑的细分领域,或持续受益于全球医药产业链重构与中国药企研发实力提升的双重红利。多位基金经理在分享创新药的投资逻辑时普遍认为,相关政策支持给予医药企业较大发展空间,创新药板块存在价值洼地,多家企业估值已具备吸引力。

2小时前

单只基金单次分红金额达84亿元,刷新纪录

6月18日,作为目前规模最大宽基指数ETF,华泰柏瑞沪深300ETF分红总金额落定,基金的单次分红金额达到84亿元,刷新境内ETF市场单次分红纪录。业内人士分析,目前,ETF产品正在不断增强分红能力,与债券基金一道,成为当前市场分红的两大核心力量。在资金结构持续演化、“长钱”加速入市的背景下,基金的分红机制日益成为投资者关注的重要指标。(证券时报)

2小时前

加拿大矿业公司Franco-Nevada暂停巴拿马矿业仲裁

当地时间6月18日,加拿大矿业公司Franco-Nevada表示,已同意暂停其针对巴拿马的仲裁程序。2024年6月27日,该公司曾根据《加拿大-巴拿马自由贸易协定》向国际投资争端解决中心提交了仲裁申请。(界面)

2小时前

中信建投:IP新消费前路坦荡,AI应用星星之火

36氪获悉,中信建投研报称,1.IP新消费前路坦荡:小情绪,大空间。内容向的新消费持续景气,中信建投认为满足三个条件就是广义的新消费,满足即刻情绪价值、高频多次消费、赛道增速快。因此从线下的潮玩和演出,到线上的游戏与音乐,都是有潜力的新消费赛道,看好长期增长空间广阔。2.AI应用星星之火,AI Agent与多模态进展领先。随着以DeepSeek为首的推理模型加速迭代,今年迎来Agent和AI视频的落地元年。

2小时前

日本6月13日当周外资净买进日本股票4743亿日元

6月19日消息,日本至6月13日当周外资买进日股4734亿日元,前值由1802亿日元修正为1798亿日元。(界面)

2小时前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询